期刊文献+

Diagnostic value of AFP-L3 and PIVKA-Ⅱin hepatocellular carcinoma according to total-AFP 被引量:56

Diagnostic value of AFP-L3 and PIVKA-Ⅱin hepatocellular carcinoma according to total-AFP
下载PDF
导出
摘要 AIM:To evaluate diagnostic value ofα-fetoprotein (AFP)-L3 and prothrombin induced by vitamin K absence-Ⅱ(PIVKA-Ⅱ)in hepatocellular carcinoma(HCC). METHODS:One hundred and sixty-eight patients during routine HCC surveillance were included in this study.Of the 168 patients,90(53.6%)had HCC including newly developed HCC(n=82)or recurrent HCC after treatment(n=8).Sera were obtained during their first evaluation for HCC development and at the time of HCC diagnosis before commencing HCC treatment.HCC was diagnosed by histological examination,appropriate imaging characteristics-computed tomography or magnetic resonance imaging.Control sera were collected from 78 patients with benign liver disease(BLD),which were obtained during routine surveillance with a suspicion of HCC.AFP,AFP-L3 and PIVKA-Ⅱwere measured in the same serum by microchip capillary electrophoresis and liquid-phase binding assay on a micro-total analysis system Wako i30 auto analyzer.The performance characteristics of three tests and combined tests for the diagnosis of HCC were obtained using receiver operating characteristic curves in all populations and subgroups with AFP<20 ng/mL. RESULTS:Of 90 HCC patients,38(42.2%)patients had AFP<20 ng/mL,20(22.2%)patients had AFP 20-200 ng/mL and 32(35.6%)patients had AFP>200 ng/mL.Of the 78 BLD patients,74(94.9%)patients had AFP<20 ng/mL.After adjustment for age and HBV infection status,AFP-L3 levels were higher in HCC than in BLD among patients with low AFP levels(<20 ng/mL)(P<0.001).In a total of 168 patients,areas under the curve(AUC)for HCC were 0.879,0.887,0.801 and 0.939 for AFP,AFP-L3,PIVKA-Ⅱand the combined markers,respectively.The combined AUC for three markers showed higher value than the AUCs of individual marker(P<0.05).AFP-L3 had higher AUC value than PIVKA-Ⅱfor HCC detection in entire patients(P =0.043).With combination of AFP-L3(cut-off>5%) and PIVKA-Ⅱ(cut-off>40 AU/L),the sensitivity were 94.4%and specificity were 75.6%in all patients.In 112 patients with low AFP levels(<20 ng/mL),AUCs of AFP-L3,PIVKA-Ⅱand combine AFP-L3 and PIVKA-Ⅱtests were 0.824,0.774 and 0.939,respectively. AFP-L3 with a cut-off value of 5%showed sensitivity of 71.1%and specificity of 83.8%,and PIVKA-Ⅱwith a cut-off value of 40 AU/L had sensitivity of 57.9%and specificity of 95.9%in patients with low AFP levels. The combination of AFP-L3 and PIVKA-Ⅱincreased the sensitivity and specificity up to 92.1%and 79.7%, respectively,in low AFP group.Combined markers detected 81.8%of early stage HCC(Union for Inter-national Cancer Control stageⅠ),86.7%of small sized tumor(<2 cm)and 91.7%of single tumor of HCC in the low AFP group.In multivariate analysis,AFP-L3 was correlated with AFP and tumor size,and PIVKA-Ⅱwas correlated with laboratory tests including serum aspartate aminotransferase,total bilirubin,platelets and albumin levels.PIVKA-Ⅱhad no correlation with AFP,AFP-L3 or tumor characteristics. CONCLUSION:Combined determination of AFP-L3 and PIVKA-Ⅱcould improve the diagnostic value for HCC detection in patients with or without increased AFP levels. AIM:To evaluate diagnostic value ofα-fetoprotein (AFP)-L3 and prothrombin induced by vitamin K absence-Ⅱ(PIVKA-Ⅱ)in hepatocellular carcinoma(HCC). METHODS:One hundred and sixty-eight patients during routine HCC surveillance were included in this study.Of the 168 patients,90(53.6%)had HCC including newly developed HCC(n=82)or recurrent HCC after treatment(n=8).Sera were obtained during their first evaluation for HCC development and at the time of HCC diagnosis before commencing HCC treatment.HCC was diagnosed by histological examination,appropriate imaging characteristics-computed tomography or magnetic resonance imaging.Control sera were collected from 78 patients with benign liver disease(BLD),which were obtained during routine surveillance with a suspicion of HCC.AFP,AFP-L3 and PIVKA-Ⅱwere measured in the same serum by microchip capillary electrophoresis and liquid-phase binding assay on a micro-total analysis system Wako i30 auto analyzer.The performance characteristics of three tests and combined tests for the diagnosis of HCC were obtained using receiver operating characteristic curves in all populations and subgroups with AFP<20 ng/mL. RESULTS:Of 90 HCC patients,38(42.2%)patients had AFP<20 ng/mL,20(22.2%)patients had AFP 20-200 ng/mL and 32(35.6%)patients had AFP>200 ng/mL.Of the 78 BLD patients,74(94.9%)patients had AFP<20 ng/mL.After adjustment for age and HBV infection status,AFP-L3 levels were higher in HCC than in BLD among patients with low AFP levels(<20 ng/mL)(P<0.001).In a total of 168 patients,areas under the curve(AUC)for HCC were 0.879,0.887,0.801 and 0.939 for AFP,AFP-L3,PIVKA-Ⅱand the combined markers,respectively.The combined AUC for three markers showed higher value than the AUCs of individual marker(P<0.05).AFP-L3 had higher AUC value than PIVKA-Ⅱfor HCC detection in entire patients(P =0.043).With combination of AFP-L3(cut-off>5%) and PIVKA-Ⅱ(cut-off>40 AU/L),the sensitivity were 94.4%and specificity were 75.6%in all patients.In 112 patients with low AFP levels(<20 ng/mL),AUCs of AFP-L3,PIVKA-Ⅱand combine AFP-L3 and PIVKA-Ⅱtests were 0.824,0.774 and 0.939,respectively. AFP-L3 with a cut-off value of 5%showed sensitivity of 71.1%and specificity of 83.8%,and PIVKA-Ⅱwith a cut-off value of 40 AU/L had sensitivity of 57.9%and specificity of 95.9%in patients with low AFP levels. The combination of AFP-L3 and PIVKA-Ⅱincreased the sensitivity and specificity up to 92.1%and 79.7%, respectively,in low AFP group.Combined markers detected 81.8%of early stage HCC(Union for Inter-national Cancer Control stageⅠ),86.7%of small sized tumor(<2 cm)and 91.7%of single tumor of HCC in the low AFP group.In multivariate analysis,AFP-L3 was correlated with AFP and tumor size,and PIVKA-Ⅱwas correlated with laboratory tests including serum aspartate aminotransferase,total bilirubin,platelets and albumin levels.PIVKA-Ⅱhad no correlation with AFP,AFP-L3 or tumor characteristics. CONCLUSION:Combined determination of AFP-L3 and PIVKA-Ⅱcould improve the diagnostic value for HCC detection in patients with or without increased AFP levels.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第3期339-346,共8页 世界胃肠病学杂志(英文版)
基金 Supported by The Industrial Core Technology Development Program funded by the Ministry of Knowledge Economy,No.10033183
关键词 α-fetoprotein PROTHROMBIN induced by VITAMIN K absence-Ⅱ HEPATOCELLULAR carcinoma Diagnosis Tumor marker α-fetoprotein Prothrombin induced by vitamin K absence-Ⅱ Hepatocellular carcinoma Diagnosis Tumor marker
  • 相关文献

参考文献13

  • 1Chaur-Shine Wang,Chin-Lin Lin,Hsi-Chang Lee,Kuan-Yang Chen,Ming-Feng Chiang,Hung-Sheng Chen,Tsung-Jung Lin.Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(39):6115-6119. 被引量:18
  • 2Yasushi Tamura,Masato Igarashi,Hirokazu Kawai,Takeshi Suda,Shinji Satomura,Yutaka Aoyagi.Clinical Advantage of Highly Sensitive On-Chip Immunoassay for Fucosylated Fraction of Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma[J].Digestive Diseases and Sciences.2010(12)
  • 3Satoru Hagiwara,Masatoshi Kudo,Toshihiko Kawasaki,Miki Nagashima,Yasunori Minami,Hobyung Chung,Toyokazu Fukunaga,Masayuki Kitano,Tatsuya Nakatani.Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma[J].Journal of Gastroenterology.2006(12)
  • 4Bae JS,Park SJ,Park KB, et a1.Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma[].Korean Journal of Internal Medicine.2005
  • 5Yamashita F,Tanaka M,Satomura S,et al.Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas[].Gastroenterology.1996
  • 6Shiraki K,Takase K,Tameda Y,et al.A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients[].Hepatology.1995
  • 7Khien V V,Mao H V,Chinh T T,et al.Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma[].International Journal of Biological Markers.2001
  • 8Oka H,Saito A,Ito K,et al.Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein[].Journal of Gastroenterology.2001
  • 9Okuda H,Obata H,Nakanishi T,et al.Production of abnormal prothrombin(des-gamma-carboxy prothrombin) by hepatocellular carcinoma, a clinical and experimental study[].Journal of Hepatology.1987
  • 10Cui,R,He,J,Zhang,F,Wang,B,Ding,H,Shen,H,Li,Y.Diagnostic value of protein induced by vitamin K absence (PIVKA II) and hepatoma-specific band of serum gamma-glutamyl transferase (GGT II) as hepatocellular carcinoma markers complementary to α-fetoprotein[].British Journal of Cancer.2003

二级参考文献33

  • 1[1]Bosch FX,Ribes J,Diaz M,Cleries R.Primary liver cancer:worldwide incidence and trends.Gastroenterology 2004; 127:S5-16
  • 2[2]Bosch FX,Ribes J,Borras J.Epidemiology of primary liver cancer.Semin Liver Dis 1999; 19:271-285
  • 3[3]Zaman SN,Melia WM,Johnson RD,Portmann BC,Johnson PJ,Williams R.Risk factors in development of hepatocellular carcinoma in cirrhosis:prospective study of 613 patients.Lancet 1985; 1:1357-1360
  • 4[4]Benvegnu L,Gios M,Boccato S,Alberti A.Natural history of compensated viral cirrhosis:a prospective study on the incidence and hierarchy of major complications.Gut 2004; 53:744-749
  • 5[5]Liaw YF,Tai DI,Chu CM,Lin DY,Sheen IS,Chen TJ,Pao CC.Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis.A prospective study.Gastroenterology 1986; 90:263-267
  • 6[6]Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol 2004; 130:417-421
  • 7[7]E1-Serag HB,Mason AC,Key C.Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996in the United States.Hepatology 2001; 33:62-65
  • 8[8]Bruix J,Sherman M,Llovet JM,Beaugrand M,Lencioni R,Burroughs AK,Christensen E,Pagliaro L,Colombo M,Rodes J.EASL panel of rxperts on HCC.Clinical management of hepatocellular carcinoma.Conclusions of the barcelona-2000EASL conference.European sssociation for the dtudy of the liver.J Hepatol 2001; 35:421-430
  • 9[9]Liebman HA,Furie BC,Tong MJ,Blanchard RA,Lo KJ,Lee SD,Coleman MS,Furie B.Des-gamma-carboxy (abnormal)prothrombin as a serum marker of primary hepatocellular carcinoma.N Engl J Med 1984; 310:1427-1431
  • 10[10]Soulier JP,Gozin D,Lefrere JJ.A new method to assay desgamma-carboxyprothrombin.Results obtained in 75 cases of hepatocellular carcinoma.Gastroenterology 1986; 91:1258-1262

共引文献17

同被引文献468

引证文献56

二级引证文献340

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部